We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

50 hedge funds and large institutions have $200M invested in Akebia Therapeutics in 2014 Q2 according to their latest regulatory filings, with 50 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,750% more capital invested

Capital invested by funds: $2.03M → $200M (+$198M)

1,567% more funds holding

Funds holding: 3 → 50 (+47)

1,567% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 3

Holders
50
Holders Change
+47
Holders Change %
+1,566.67%
% of All Funds
1.44%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
50
Increased
–
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
+$36.5M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$24.5M
3
HM
HealthCor Management
New York
+$21.7M
4
RCM
RA Capital Management
Massachusetts
+$14.4M
5
Franklin Resources
Franklin Resources
California
+$12.3M

Top Sellers

Rank Fund Capital Flow
1
GGHC
Gilder Gagnon Howe & Co
New York
-$1.22M
2
LCM
Laurion Capital Management
New York
-$449K
3
Citadel Advisors
Citadel Advisors
Florida
-$361K
Name Holding Trade Value Shares
Change 		Change in
Stake
U
26
UBS
Switzerland
$465K +$403K +16,731 New
Charles Schwab
27
Charles Schwab
California
$462K +$400K +16,613 New
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$411K +$356K +14,777 New
California State Teachers Retirement System (CalSTRS)
29
California State Teachers Retirement System (CalSTRS)
California
$397K +$344K +14,300 New
BPC
30
Banque Pictet & Cie
Switzerland
$387K +$336K +13,942 New
BlackRock
31
BlackRock
New York
$326K +$282K +11,698 New
TA
32
Teachers Advisors
New York
$307K +$266K +11,062 New
Jane Street
33
Jane Street
New York
$306K +$265K +11,000 New
MLICM
34
Metropolitan Life Insurance Company (MetLife)
New York
$258K +$224K +9,285 New
ARTA
35
A.R.T. Advisors
New York
$256K +$223K +9,246 New
NFA
36
Nationwide Fund Advisors
Ohio
$166K +$144K +5,971 New
Manulife (Manufacturers Life Insurance)
37
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$144K +$125K +5,175 New
AIG
38
American International Group
New York
$142K +$123K +5,124 New
AllianceBernstein
39
AllianceBernstein
Tennessee
$100K +$86.7K +3,600 New
Wells Fargo
40
Wells Fargo
California
$96K +$83.2K +3,457 New
Barclays
41
Barclays
United Kingdom
$67K +$59.7K +2,481 New
Fifth Third Bancorp
42
Fifth Third Bancorp
Ohio
$51K +$44K +1,826 New
TRCT
43
Tower Research Capital (TRC)
New York
$46K +$39.6K +1,645 New
BJ
44
BlackRock Japan
Japan
$38K +$32.8K +1,363 New
VFA
45
Virtus Fund Advisers
Connecticut
$19K +$16.1K +668 New
MA
46
MCF Advisors
Kentucky
$18K +$22K +913 New
ST
47
Stifel Trust
Missouri
$3K +$2.41K +100 New
WA
48
WFG Advisors
Texas
$3K +$2.41K +100 New
Citigroup
49
Citigroup
New York
$3K +$2.55K +106 New
Deutsche Bank
50
Deutsche Bank
Germany
$1K +$939 +39 New
1
2
3

AKBA Hedge Fund Activity: Q2 2014 in Review

50 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q2 2014, worth a combined $200M — up 9,750% from $2.03M a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new AKBA positions and 3 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $36.5M. The largest seller was Gilder Gagnon Howe & Co, exiting entirely with an estimated $1.22M sold.

  • 50 institutional investors held Akebia Therapeutics (AKBA) as of Q2 2014, up from 3 in Q1 2014.
  • Funds reported $200M of Akebia Therapeutics stock for Q2 2014, up 9,750% quarter-over-quarter.
  • 50 funds opened new Akebia Therapeutics positions in Q2 2014 and 3 closed out, a net change of +47 holders.
  • The largest Akebia Therapeutics buyer in Q2 2014 was Novo Holdings A/S, an estimated $36.5M added.
  • The largest Akebia Therapeutics seller in Q2 2014 was Gilder Gagnon Howe & Co, an estimated $1.22M sold.

Based on aggregated 13F filings for Q2 2014.